Capsid of HIV-1 behaves like cell’s cargo receptor to enter the nucleus
Biologists demonstrate that HIV-1 capsid acts like a Trojan horse to pass viral cargo across the nuclear pore.
Biologists demonstrate that HIV-1 capsid acts like a Trojan horse to pass viral cargo across the nuclear pore.
Human volunteers will soon begin receiving an HIV vaccine that contains an adjuvant developed in Irvine’s lab, which helps to boost B cell responses to the vaccine.
Neural network identifies synergistic drug blends for treating viruses like SARS-CoV-2.
Selective global honor supports early-career scientists and engineers in taking on new pursuits.
Using this computational system, researchers can identify viral protein sequences that could make better vaccine targets.
Differently shaped RNA molecules allow HIV to express different genes from the same RNA sequence.
Researchers apply network theory to HIV protein structure, uncovering a vital link between connectivity and protective immune response.
Replacing daily pills with a weekly regimen could help patients stick to their dosing schedule.
Youth-to-youth program teaches girls about the increased odds of contracting HIV from older men.
MIT students partner with a clinic in Togo to improve health care for HIV/AIDS patients.
Christopher Love uses microscale technology to isolate rare cells, yielding insight into human disease.
Study yields insight into generating antibodies that target different strains of HIV.
New study reveals how a potential HIV drug exacts its toll on viral populations.
New MIT vaccines that catch a ride to immune cell depots could help fight cancer and HIV.